ImmuPharma PLC (LON:IMM)
4.30p
Spriggl Score: Weak— see the number + sub-scores with a free Spriggl account
Last 30 trading days
Spriggl AI Verdict
“Lupus drug partnership remains elusive despite fresh cash extending runway to late 2028.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company's lead product candidate includes P140…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £26.9M
Recent dividends
- 14 Dec 20213.00p
Get the full Spriggl analysis — free
Sign up for a free Spriggl account to unlock the full Spriggl Score breakdown, screener, watchlist, and AI investment analysis on ImmuPharma PLC and 1,600+ UK and US stocks.
Start free